Growth inhibition effect of peptide P110 plus cisplatin on various cancer cells and xenotransplanted tumors in mice

Li,Ming; Wang,Jun; Tan,Shi‑Yun; Chen,Jian‑Hua; Cui,Wei; Chen,Zhi‑Qiang; Zhang,Jian

doi:10.3892/mmr.2013.1343

Growth inhibition effect of peptide P110 plus cisplatin on various cancer cells and xenotransplanted tumors in mice

Authors:
- Ming Li
- Jun Wang
- Shi‑Yun Tan
- Jian‑Hua Chen
- Wei Cui
- Zhi‑Qiang Chen
- Jian Zhang
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Wuhan KatyGen Pharmaceuticals, Inc., Wuhan, Hubei 430074, P.R. China, Department of Chemistry, Graduate University of Chinese Academy of Sciences, Beijing 100049, P.R. China
Published online on: February 26, 2013 https://doi.org/10.3892/mmr.2013.1343
Pages: 1149-1154

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The combined use of currently used anticancer genotoxins with other drugs is a therapeutic tool for potentially increasing the efficacy of the genotoxins. In the present study, the effects of a RasGAP‑derived peptide, P110 (RasGAP301‑316), designed to target Ras‑GTPase activating protein SH3 domain‑binding proteins (G3BPs), on the chemotherapeutic agent, cisplatin (DDP), were examined. P110 was demonstrated to enhance the effect of DPP in vitro and in vivo. The results indicate that P110 significantly increased the DDP‑induced apoptosis in SGC‑7901, HCT‑116, HeLa and A‑549 cells. Furthermore, P110 combined with DDP significantly suppressed the growth of C26 xenograft tumors in a dose‑dependent manner. This synergistic effect may be associated with DDP‑induced apoptosis, involving the downregulation of Bcl‑2 and the upregulation of Bax, cytochrome c and caspase‑3. The results of the present study indicate that P110, in combination with chemotherapeutics, is likely to represent a potential therapeutic strategy for cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Yamaoka Y, Kato M and Asaka M: Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med. 47:1077–1083. 2008. View Article : Google Scholar : PubMed/NCBI
3	Center MM, Jemal A and Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 18:1688–1694. 2009. View Article : Google Scholar : PubMed/NCBI
4	Legge F, Fuoco G, Lorusso D, et al: Pharmacotherapy of cervical cancer. Expert Opin Pharmacother. 11:2059–2075. 2010. View Article : Google Scholar : PubMed/NCBI
5	Parkin DM: International variation. Oncogene. 23:6329–6340. 2004. View Article : Google Scholar
6	Schiff D, Wen PY and van den Bent MJ: Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol. 6:596–603. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kaushal GP, Kaushal V, Herzog C and Yang C: Autophagy delays apoptosis in renal tubular epithelial cells in cisplatin cytotoxicty. Autophagy. 4:710–712. 2008. View Article : Google Scholar : PubMed/NCBI
8	Lee S, Kim W, Moon SO, et al: Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant. 21:2096–2105. 2006. View Article : Google Scholar : PubMed/NCBI
9	Yao X, Panichpisal K, Kurtzman N and Nugent K: Cisplatin nephrotoxicity: a review. Am J Med Sci. 334:115–124. 2007. View Article : Google Scholar
10	Zhang HZ, Liu JG, Wei YP, et al: Expression of G3BP and RhoC in esophageal squamous carcinoma and their effect on prognosis. World J Gastroenterol. 13:4126–4130. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ning JY, You JF, Pei F, et al: Monoclonal antibody against G3BP: preparation, characterization and its application in analysis of human tumors. Zhonghua Bing Li Xue Za Zhi. 34:215–219. 2005.(In Chinese).
12	Cui W, Wei Z, Chen Q, et al: Structure-based design of peptides against G3BP with cytotoxicity on tumor cells. J Chem Inf Model. 50:380–387. 2010. View Article : Google Scholar : PubMed/NCBI
13	Chen JH, Huang YU, Xiong YU and Chen CH: Peptides or derivatives which treat or prevent cancers and the application CN Patent 200910163852. Issued August 11, 2009.
14	Zhang J, Tan SY, Chen JH, et al: Polypeptide A28 enhances cytotoxic effect of cisplatin on colon cancer cell line HCT-116. Chin J Cancer Biother. 17:318–321. 2010.(In Chinese).
15	Kaufmann SH, Peereboom D, Buckwalter CA, et al: Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 88:734–741. 1996. View Article : Google Scholar : PubMed/NCBI
16	Chou TC, Motzer RJ, Tong Y and Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 86:1517–1524. 1994. View Article : Google Scholar : PubMed/NCBI
17	Guitard E, Parker F, Millon R, et al: G3BP is overexpressed in human tumors and promotes S phase entry. Cancer Lett. 162:213–221. 2001. View Article : Google Scholar : PubMed/NCBI
18	Liu Y, Zheng J, Fang W, et al: Identification of metastasis associated gene G3BP by differential display in human cancer cell sublines with different metastatic potentials G3BP as highly expressed in non-metastatic. Chin Med J (Engl). 114:35–38. 2001.PubMed/NCBI
19	French J, Stirling R, Walsh M and Kennedy HD: The expression of Ras-GTPase activating protein SH3 domain-binding proteins, G3BPs, in human breast cancers. Histochem J. 34:223–231. 2002. View Article : Google Scholar : PubMed/NCBI
20	Barnes CJ, Li F, Mandal M, et al: Heregulin induces expression, ATPase activity and nuclear localization of G3BP, a Ras signaling component, in human breast tumors. Cancer Res. 62:1251–1255. 2002.PubMed/NCBI
21	Parker F, Kenigsberg M, Duchesne M, et al: Monoclonal antibodies directed against the G3BP protein and uses US Patent 7001980B1 [P]. Issued February 21, 2006.
22	Parker F, Maurier F, Delumeau I, et al: A Ras-GTPase-activating protein SH3-domain-binding protein. Mol Cell Biol. 16:2561–2569. 1996.PubMed/NCBI
23	Kennedy D, French J, Guitard E, et al: Characterization of G3BPs: tissue specific expression, chromosomal localisation and rasGAP(120) binding studies. J Cell Biochem. 84:173–187. 2001. View Article : Google Scholar : PubMed/NCBI
24	Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885. 2005. View Article : Google Scholar : PubMed/NCBI
25	Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
26	Chen M and Wang J: Initiator caspases in apoptosis signaling pathways. Apoptosis. 7:313–319. 2002. View Article : Google Scholar
27	Green DR: Apoptotic pathways: ten minutes to dead. Cell. 121:671–674. 2005. View Article : Google Scholar : PubMed/NCBI
28	Michod D, Yang JY, Chen J, et al: A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells. Oncogene. 23:8971–8978. 2004. View Article : Google Scholar : PubMed/NCBI
29	Zhang H, Zhang S, He H, et al: RasGAP-derived peptide 38GAP potentiates the cytotoxicity of cisplatin through inhibitions of Akt, ERK and NF-κB in colon carcinoma HCT116 cells. Cancer Lett. 308:62–70. 2011.PubMed/NCBI